#Life Sciences

2개의 글

May 15, 2026

TMO Thermo Fisher Stock Outlook 2026: The Price of Owning Science Infrastructure

Thermo Fisher Scientific (TMO) stock analysis for 2026: $45.2B TTM revenue, P/E 24.6x, CDMO recovery cycle, NIH budget headwinds, analyst target $611, and what the 30% drop from highs actually means for investors.

TMO Thermo Fisher Life Sciences

May 11, 2026

DHR Danaher Stock Outlook 2026: Bioprocessing Recovery and the Return of the DBS Engine

Danaher stock analysis for 2026: bioprocessing destocking cycle resolution, Cytiva and Pall recovery thesis, Abcam acquisition integration, Cepheid post-pandemic diagnostic growth, Danaher Business System advantage, and valuation framework for the recovery story.

DHR Danaher Bioprocessing